Predictive Oncology Partners with Every Cure for AI-driven Drug Repurposing.

Predictive Oncology and Every Cure announce a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes and save lives. Predictive Oncology will utilize its AI-driven machine learning capabilities to rapidly screen drugs against a broad range of tumor types, predicting patient response to anti-cancer therapies. This collaboration aims to support drug developers in expanding and replenishing their pipelines.

PITTSBURGH, Sept. 02, 2025 — Predictive Oncology Inc. (NASDAQ: POAI) and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, have announced a strategic collaboration aimed at accelerating drug repurposing for cancer patients. The partnership leverages the AI-driven capabilities of Predictive Oncology and the nonprofit’s mission to save lives through repurposed drugs [1].

Predictive Oncology, a leader in AI-driven drug development and discovery, will utilize its advanced machine learning (ML) models to rapidly screen a broad range of tumor types against existing FDA-approved drugs. The company’s platform, PEDAL, predicts patient tumor drug response with 92% accuracy, enabling the identification of promising drug candidates for repurposing [1].

Every Cure, on the other hand, is committed to using AI to identify and validate new uses for existing drugs, aiming to deliver treatments to patients in months rather than decades. The nonprofit’s AI models use knowledge graphs, large language models, and real-world medical data to pinpoint the most promising opportunities for drug repurposing [1].

The collaboration will see Predictive Oncology provide data from its vast biobank of more than 150,000 tumor samples across various cancer types to Every Cure. This data will be used to evaluate and prioritize potential drug candidates for repurposing, aligning closely with Every Cure’s mission to alleviate suffering for millions of people battling diseases with no approved treatments [1].

“This strategic collaboration is a testament to the complementary strengths of our organizations,” said Dr. Arlette Uihlein, SVP, Translational Medicine and Drug Discovery, Medical Director at Predictive Oncology. “Together, we can accelerate drug repurposing efforts, making a meaningful difference in the lives of cancer patients” [1].

Every Cure’s CEO, Raymond F. Vennare, echoed this sentiment, stating, “This partnership not only supports our mission but also advances our cause by leveraging Predictive Oncology’s unique assets and capabilities” [1].

The collaboration aims to reduce the time and cost associated with drug repurposing, making life-saving treatments more accessible and affordable. By combining Predictive Oncology’s AI-driven screening capabilities with Every Cure’s expertise in drug repurposing, the partnership seeks to overcome barriers to these efforts and promote equitable and economically feasible healthcare solutions [1].

References:
[1] https://www.globenewswire.com/news-release/2025/09/04/3144558/37244/en/Predictive-Oncology-and-Every-Cure-Announce-a-Strategic-Collaboration-to-Pursue-Drug-Repurposing-for-Cancer-Patients.html